TripAdvisor (TRIP) PT Raised to $40 at Stifel

TripAdvisor (TRIP) PT Raised to $43 at UBS

UBS raised its price target on TripAdvisor (NASDAQ: TRIP) to $43.00 (from $35.00) while maintaining a Neutral rating.

TripAdvisor (TRIP) PT Raised to $36 at Credit Suisse

Credit Suisse raised its price target on TripAdvisor (NASDAQ: TRIP) to $36.00 (from $33.00) while maintaining a Underperform rating.

TripAdvisor (TRIP) PT Raised to $30 at Goldman Sachs

Goldman Sachs raised its price target on TripAdvisor (NASDAQ: TRIP) to $30.00 (from $27.00) while maintaining a Sell rating.

TripAdvisor (TRIP) PT Raised to $45 at Susquehanna

Susquehanna raised its price target on TripAdvisor (NASDAQ: TRIP) to $45.00 (from $28.00) while maintaining a Neutral rating.

Analyst Shyam Patil commented, "PCLN stabilization drives 4Q upsidebut visibility remains poor and structural challenges still likely to cause volatility in numbers."

TripAdvisor (TRIP) PT Raised to $48 at Citi on 4Q Report; 'Improved Margins, but Mixed Growth Dynamic'

Citi raised its price target on TripAdvisor (NASDAQ: TRIP) to $48.00 (from $34.00) while maintaining a Neutral rating, following the company's fourth quarter earnings report.

Analyst Mark May notes a positive outlook on the shares, as the company reported fourth quarter revenues above consensus projections driven... More

TripAdvisor (TRIP) PT Raised to $48 at Ascendiant Capital

Ascendiant Capital raised its price target on TripAdvisor (NASDAQ: TRIP) to $48.00 (from $38.00) while maintaining a Buy rating.

Analyst Ed Woo commented, "Q4 about inline and flat 2018 guidance. Near-term investments and revenue issues likely to temper positive longer-term growth and valuation."

Pre-Open Movers 02/15: (AMAG) (SEDG) (TEVA) Higher; (CDMO) (THS) (NTAP) Lower (more...)

Today's Pre-Open Movers

Avid Bioservices, Inc. (NASDAQ: CDMO) 27.1% LOWER; announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $2.25 per share

AMAG Pharmaceuticals (AMAG) (NASDAQ: AMAG) 18.7%... More

TripAdvisor (TRIP): Hotel Stabilization Drives PT Increase - Piper Jaffray

Piper Jaffray analyst, Michael Olson, reiterated his Neutral rating on shares of TripAdvisor (NASDAQ: TRIP) and raised his price target to $47 from $40 after the company reported strong Q4'17 results with revenue and EBITDA above consensus.

The analyst stated "Revenue per... More

TripAdvisor (TRIP) PT Raised to $47 at Piper Jaffray

Piper Jaffray raised its price target on TripAdvisor (NASDAQ: TRIP) to $47.00 (from $40.00) while maintaining a Neutral rating.

After-Hours Stock Movers 02/14: (TRIP) (TEVA) (CSCO) Higher; (CDMO) (NTAP) (SPWR) Lower (more...)

Today's After-Hours Movers

TripAdvisor (NASDAQ: TRIP) 16.5% HIGHER; reported Q4 EPS of $0.06, $0.08 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $321 million versus the consensus estimate of $309.42 million. The company approved a $250 million buyback.

Avid Bioservices, Inc. (NASDAQ: CDMO) 16.3% LOWER; commenced an underwritten public offering of its common stock. Avid Bioservices also intends to grant the underwriter a 30-day option to purchase from it up to an additional 15% of the shares... More

TripAdvisor (TRIP) Misses Q4 EPS by 8c, Revenue Beats

TripAdvisor (NASDAQ: TRIP) reported Q4 EPS of $0.06, $0.08 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $321 million versus the consensus estimate of $309.42 million.

During Q4 and 2017 we continued to make progress along our key initiatives, said Chief Executive Officer Steve Kaufer.... More